Top

Published in:

Open Access 31-05-2022 | Ulcerative Colitis | Review Article

Filgotinib: A Clinical Pharmacology Review

Authors: Florence Namour, Kacey Anderson, Cara Nelson, Chantal Tasset

Published in: Clinical Pharmacokinetics | Issue 6/2022

Abstract

Filgotinib (GS-6034, formerly GLPG0634; Jyseleca^®) is an oral, preferential Janus kinase (JAK)-1 inhibitor. Preferential inhibition of JAK1 modulates a subset of proinflammatory cytokines within the JAK–signal transducer and activator of transcription pathway, which differ from those inhibited by JAK2 or JAK3. Filgotinib is absorbed extensively and rapidly after oral dosing and is metabolized by carboxylesterase isoform 2 to form its primary active metabolite, GS-829845. The primary metabolite has a similar JAK1 selectivity profile but reduced activity (by 10-fold) and increased systemic exposure (approximately 16- to 20-fold) compared with the parent compound. Both the parent and the metabolite demonstrate low binding to plasma proteins in humans (< 60%). Systemic exposures of filgotinib and its primary metabolite increase dose proportionally over a 50- to 200-mg once-daily dose range. Food does not affect the pharmacokinetics of filgotinib. Consistent with their terminal elimination half-lives (4.9–10.7 h for filgotinib and 19.6–27.3 h for the primary metabolite), steady state in plasma is reached by day 2 for filgotinib and day 4 for its metabolite. Filgotinib is mainly eliminated in the urine as the metabolite (> 80%). Intrinsic factors such as age, sex, race, mild renal impairment, and mild-to-moderate hepatic impairment have either no or minimal impact on the pharmacokinetics of filgotinib and its primary metabolite. Filgotinib has a low drug–drug interaction potential, without clinically significant interactions with commonly coadministered medications in patients with inflammatory diseases. Both filgotinib and its primary metabolite are substrates of P-glycoprotein (P-gp); however, coadministration with P-gp inhibitors and inducers does not affect filgotinib pharmacokinetics sufficiently to warrant dose adjustment. Neither filgotinib nor its primary metabolite affect the corrected QT interval (calculated using Fridericia’s correction formula). Filgotinib is approved for the treatment of rheumatoid arthritis and ulcerative colitis in Europe, the UK, and Japan.

Isomäki P, Junttila I, Vidqvist KL, Korpela M, Silvennoinen O. The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels. Rheumatology (Oxford). 2015;54:1103–13. https://doi.org/10.1093/rheumatology/keu430.CrossRef

Neurath M. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:688. https://doi.org/10.1038/nrgastro.2017.138.CrossRefPubMed

Schwartz DM, Bonelli M, Gadina M, O’Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36. https://doi.org/10.1038/nrrheum.2015.167.CrossRefPubMed

Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol. 2005;32:1650–3.PubMed

Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521–46. https://doi.org/10.1007/s40265-017-0701-9.CrossRefPubMedPubMedCentral

Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13:693–703. https://doi.org/10.1080/1744666X.2017.1291342.CrossRefPubMed

Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266–75. https://doi.org/10.1016/S0140-6736(16)32537-5.CrossRefPubMed

O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii111–5. https://doi.org/10.1136/annrheumdis-2012-202576.CrossRef

Sandborn WJ, Feagan BG, De Hertogh G, Chen G, French DF, Huntzicker EG, et al. Filgotinib (GLPG0634, GS-6034), a JAK-1 selective inhibitor, significantly reduces gut tissue PSTAT3 in Crohn’s disease patients. Gastroenterology. 2017;152(Suppl 1):S602.CrossRef

10.

Gilead Sciences. Jyseleca summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf. Accessed 9 Oct 2021.

11.

Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signaling by filgotinib, upadacitinib, tofacitinib, and baricitinib. Ann Rheum Dis. 2021;80:865–75. https://doi.org/10.1136/annrheumdis-2020-219012.CrossRefPubMed

12.

Galien R, Vayssiere B, De Vos S, Auberval M, Vandeghinste N, Dupont S, et al. Analysis of the JAK1 selectivity of GLPG0634 and its main metabolite in different species, healthy volunteers and rheumatoid arthritis patients. Arthritis Rheum. 2013;65(10 Suppl):S209–10.

13.

Namour F, Diderichsen PM, Cox E, Vayssière B, Van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of Phase IIB dose selection. Clin Pharmacokinet. 2015;54:859–74. https://doi.org/10.1007/s40262-015-0240-z.CrossRefPubMedPubMedCentral

14.

Genovese MC, Kalunian K, Gottenberg J-E, Mozaffarian N, Bartok B, Matzkies F, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322:315–25. https://doi.org/10.1001/jama.2019.9055.CrossRefPubMedPubMedCentral

15.

Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80:848–58. https://doi.org/10.1136/annrheumdis-2020-219214.CrossRefPubMed

16.

Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;80:727–38. https://doi.org/10.1136/annrheumdis-2020-219213.CrossRefPubMed

17.

Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372–84. https://doi.org/10.1016/S0140-6736(21)00666-8.

18.

European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Assessment report: Jyseleca. EMA/424374/2020. Available from: https://www.ema.europa.eu/en/documents/assessment-report/jyseleca-epar-public-assessment-report_en.pdf. Accessed 4 Feb 2021.

19.

Menet CJ, Fletcher SR, Van Lommen G, Geney R, Blanc J, Smits K, et al. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. J Med Chem. 2014;57:9323–42. https://doi.org/10.1021/jm501262q.CrossRefPubMed

20.

Anderson K, Xin Y, Zheng H, Yun C, Kwan E, Qin A, et al. Filgotinib, a JAK1 inhibitor, has no effect on QT interval in healthy subjects. Clin Pharmacol Drug Dev. 2020;9:32–40. https://doi.org/10.1002/cpdd.755.CrossRefPubMed

21.

Anderson K, Zheng H, Kotecha M, Cuvin J, Scott B, Sharma S, et al. The relative bioavailability and effects of food and acid-reducing agents on filgotinib tablets in healthy subjects. Clin Pharmacol Drug Dev. 2019;8:585–94. https://doi.org/10.1002/cpdd.659.CrossRefPubMed

22.

Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191:3568–77. https://doi.org/10.4049/jimmunol.1201348.CrossRefPubMed

23.

Anderson K, Zheng H, Medzihradsky O, Yizhao L, Qin A, Kearney B, et al. Pharmacokinetics and short-term safety of filgotinib, a selective Janus kinase 1 inhibitor, in subjects with moderate hepatic impairment. Ann Rheum Dis. 2019;78(Suppl 2):331.

24.

Namour F, Desrivot J, Van der Aa A, Harrison P, Tasset C, van't Klooster G. Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions. Drug Metab Lett. 2016;10:38–48. https://doi.org/10.2174/1872312810666151223103353.CrossRefPubMed

25.

Di L. The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr Drug Metab. 2019;20:91–102. https://doi.org/10.2174/1389200219666180821094502.CrossRefPubMed

26.

Namour F, Fagard L, Van der Aa A, Harrison P, Xin Y, Tasset C. Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. Br J Clin Pharmacol. 2018;84:2779–89. https://doi.org/10.1111/bcp.13726.CrossRefPubMedPubMedCentral

27.

Kavanaugh A, Westhovens RR, Winthrop KL, Lee SJ, Tan Y, An D, et al. Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs. J Rheumatol. 2021;48:1230–8. https://doi.org/10.3899/jrheum.201183.CrossRefPubMed

28.

Tanaka Y, Kavanaugh A, Wicklund J, McInnes IB. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: an overview from clinical trials. Mod Rheumatol. 2022;32:1–11. https://doi.org/10.1080/14397595.2021.1902617.CrossRefPubMed

29.

Namour F, Vayssiere B, Galien R, Fagard L, Van der Aa A, Harrison P, et al. Filgotinib (GLPG0634), a selective JAK1 inhibitor, shows similar PK and PD profiles in Japanese and Caucasian healthy volunteers. Ann Rheum Dis. 2015;74(Suppl 2):1063–4.CrossRef

30.

Imai T, Taketani M, Shii M, Hosokawa M, Chiba K. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos. 2006;34:1734–41. https://doi.org/10.1124/dmd.106.009381.CrossRefPubMed

31.

Hsueh C-H, Anderson K, Shen G, Yun C, Qin A, Othman AA. Evaluation of the potential drug interactions mediated through P-gp, OCT2 and MATE1/2K with filgotinib in healthy subjects. Clin Trans Sci. 2022;15:361–70. https://doi.org/10.1111/cts.13152.CrossRef

32.

Anderson K, Nelson CH, Gong Q, Alani M, Tarnowski T, Othman AA. Assessment of the effect of filgotinib on the pharmacokinetics of atorvastatin, pravastatin, and rosuvastatin in healthy adult participants. Clin Pharmacol Drug Dev. 2022;11:235–45. https://doi.org/10.1002/cpdd.1015.

33.

Barbosa ACS, Feng Y, Yu C, Huang M, Xie W. Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases. Expert Opin Drug Metab Toxicol. 2019;15:329–39. https://doi.org/10.1080/17425255.2019.1588884.CrossRefPubMedPubMedCentral

34.

Tong MH, Jiang H, Liu P, Lawson JA, Brass LF, Song WC. Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nat Med. 2005;11:153–9. https://doi.org/10.1038/nm1184.CrossRefPubMed

35.

Begley R, Anderson K, Watkins TR, Weng W, Ampaw L, Qin A, et al. Lack of drug-drug interaction between filgotinib, a selective JAK1 inhibitor, and oral hormonal contraceptives levonorgestrel/ethinyl estradiol in healthy volunteers. Clin Pharmacol Drug Dev. 2020;10:376–83. https://doi.org/10.1002/cpdd.870.CrossRefPubMed

36.

Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76:1009–19. https://doi.org/10.1136/annrheumdis-2016-210105.CrossRefPubMed

37.

Westhovens R, Taylor PC, Alten R, Pavlova D, Enríquez-Sosa F, Mazur M, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76:998–1008. https://doi.org/10.1136/annrheumdis-2016-210104.CrossRefPubMed

Title: Filgotinib: A Clinical Pharmacology Review
Authors: Florence Namour
Kacey Anderson
Cara Nelson
Chantal Tasset
Publication date: 31-05-2022
Publisher: Springer International Publishing
Keywords: Ulcerative Colitis
Pharmacokinetics
Rheumatoid Arthritis
Published in: Clinical Pharmacokinetics / Issue 6/2022
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-022-01129-y

At a glance: The STEP trials

Springer Medicine

Filgotinib: A Clinical Pharmacology Review

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2022

Correction to: Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria

HDI Highlighter, The First Intelligent Tool to Screen the Literature on Herb–Drug Interactions

Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study)

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants

Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients

A Review of Population Pharmacokinetic Analyses of Linezolid